|
![]() |
|||
|
||||
OverviewFull Product DetailsAuthor: Donald C. Lo , Robert E. HughesPublisher: Taylor & Francis Inc Imprint: CRC Press Inc Volume: v. 45 Dimensions: Width: 15.60cm , Height: 2.30cm , Length: 23.40cm Weight: 0.612kg ISBN: 9780849390005ISBN 10: 0849390001 Pages: 340 Publication Date: 02 July 2010 Audience: Professional and scholarly , Professional & Vocational Format: Hardback Publisher's Status: Active Availability: In Print ![]() This item will be ordered in for you from one of our suppliers. Upon receipt, we will promptly dispatch it out to you. For in store availability, please contact us. Table of ContentsIntroduction. Clinical Overview of HD. Genetics of HD. Molecular Pathology of Hungtingtin Function. Genomic, Protemoics, and Metabonomics of HD. High-throughput Screening in HD. High-content Screening in HD. Animal Models for HD. Pharmaceutical Development for HD. HD Clinical Trials.ReviewsThe book is written lucidly by authorities in their respective fields, covering clinical features, pathogenic mechanisms, protein interactions, preclinical models, biomarkers, small molecules and other approaches (eg, recombinant antibodies), screening strategies, and drug development. Informative figures and tables are provided, and reproduction of key figures as a set of colour plates provides a useful centrepiece. One unifying message is that the polyglutamine xpansion leads to a complex cascade of diverse molecular and cellular events, the progress of which is difficult to slow or halt. Innovative approaches described, such as the target validation process of the Cure Huntington's Disease Initiative (CHDI) Foundation, will be of interest to those studying other neurological diseases. --Anthony J Hannan, writing in The Lancet Neurology, March 2011 The book is written lucidly by authorities in their respective fields, covering clinical features, pathogenic mechanisms, protein interactions, preclinical models, biomarkers, small molecules and other approaches (eg, recombinant antibodies), screening strategies, and drug development. Informative figures and tables are provided, and reproduction of key figures as a set of colour plates provides a useful centrepiece. One unifying message is that the polyglutamine xpansion leads to a complex cascade of diverse molecular and cellular events, the progress of which is difficult to slow or halt. Innovative approaches described, such as the target validation process of the Cure Huntington's Disease Initiative (CHDI) Foundation, will be of interest to those studying other neurological diseases.--Anthony J Hannan, writing in The Lancet Neurology, March 2011 Author InformationDuke University Medical Center, Durham, North Carolina, USA Buck Institute for Age Research, Novato, California, USA Tab Content 6Author Website:Countries AvailableAll regions |